Skip to main content

Clinically Significant Interactions of Psychotropic Agents with Antipsychotic Drugs

Drug Safety volume 15, pages 333–346 (1996)Cite this article

Summary

Various psychotropic drugs are commonly combined with antipsychotic agents. Such combinations can induce pharmacodynamically based, presumably additive, beneficial (e.g. sedative or mood-altering) effects or adverse autonomic, cardiac depressant and CNS intoxicating effects.

Clinically significant interactions also arise through competition with or induction of hepatic microsomal cytochrome P450 (CYP) enzymes, particularly the CYP1A2 and CYP2D6 isozymes by which most antipsychotics are oxidised. Such pharmacokinetic interactions can elevate circulating concentrations of antipsychotics (both typical agents and the atypical antipsychotic clozapine) to potentially toxic ranges, which may lead to increased risks of adverse effects. Such interactions occur particularly with serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor antidepressants. Metabolic interactions that lead to lesser increases in antipsychotic concentrations may arise in combining these drugs with other antidepressants, benzodiazepines or propranolol. In contrast, most anticonvulsants, except valproic acid (sodium valproate), induce the oxidative metabolism of antipsychotics and can lower their plasma concentrations to potentially subtherapeutic levels, with unpredictable increases after their discontinuation.

Since simultaneous use of multiple psychotropic agents is increasingly common, special caution is required to avoid untoward consequences of interactive adverse effects due to drug interactions, which can sometimes be severe or life-threatening.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Baldessarini RJ, Kando J, Centorrino F. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry 1995; 152: 1038–44

    PubMed  CAS  Google Scholar 

  2. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antipsychotic and antianxiety agents. In: Harden W, Rudin W, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacologic basis of therapeutics. New York: McGraw-Hill, 1996: 399–430

    Google Scholar 

  3. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993; 13: 57–67

    Article  PubMed  CAS  Google Scholar 

  4. Goff DC, Baldessarini RJ. Antipsychotics. In: Ciraulo DA, Shader RI, Greenblatt DJ, et al., editors. Drug interactions in psychiatry. Baltimore: Williams & Wilkins, 1995: 129–74

    Google Scholar 

  5. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Arch Gen Psychiatry 1988; 45: 79–91

    Article  PubMed  CAS  Google Scholar 

  6. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994; 55 (12 Suppl.): 38–45

    PubMed  Google Scholar 

  7. Pollock B. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry 1994; 2: 204–13

    Article  CAS  Google Scholar 

  8. Nemeroff C, De Vane C, Pollock B. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311–20

    PubMed  CAS  Google Scholar 

  9. Turano P, Turner WJ, Manian AA. Thin layer chromatography of chlorpromazine metabolites. J Chromatography 1973; 75: 277–93

    Article  CAS  Google Scholar 

  10. Jorgensen A. Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges J, Chasseaud L, editors. Progress in drug metabolism. Vol. 11. Bristol, PA: Taylor & Francis, 1986: 111–74

    Google Scholar 

  11. Aravagiri M, Marder SR, Yuwiler A, et al. Distribution of flu-phenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology 1995; 13: 235–47

    Article  PubMed  CAS  Google Scholar 

  12. Ereshefsky L, Davis CM, Harrington CA. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol 1984; 4: 138–42

    Article  PubMed  CAS  Google Scholar 

  13. Korpi ER, Wyatt RJ. Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat. Psychopharmacology 1984; 83: 34–7

    Article  PubMed  CAS  Google Scholar 

  14. Ko GN, Korpi ER, Kirch DG. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. J Clin Psychopharmacol 1989; 9: 186–90

    Article  PubMed  CAS  Google Scholar 

  15. Straw GM, Bigelow LB, Kirch DG. Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid. J Clin Psychopharmacol 1989; 9: 130–2

    Article  PubMed  CAS  Google Scholar 

  16. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450-3A in psychopharmacology. J Clin Psychopharmacol 1995; 15: 387–98

    Article  PubMed  CAS  Google Scholar 

  17. Dahl SG. Plasma level monitoring of antipsychotic drugs: clinical utility. Clin Pharmacokinet 1986; 11: 36–61

    Article  PubMed  CAS  Google Scholar 

  18. Midha KK, Hubbard JW, May PRA. Role of the analytical biochemist in resistant schizophrenia. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Wiesbaden: Vieweg, 1988: 56–64

    Google Scholar 

  19. Brøsen K, Sjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P450-1A2. Biochem Pharmacol 1993; 45: 1211–4

    Article  PubMed  Google Scholar 

  20. Daniel DG, Randolph C, Jaskiw G, et al. Coadministration of fluvoxamine increases serum concentration of haloperidol. J Clin Psychopharmacol 1994; 14: 340–3

    Article  PubMed  CAS  Google Scholar 

  21. Hiemke C, Weigmann H, Hartter S, et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279–81

    Article  PubMed  CAS  Google Scholar 

  22. Jerling M, Lindstrom L, Bondesson U. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine. Ther Drug Monit 1994; 16: 368–74

    Article  PubMed  CAS  Google Scholar 

  23. Centorrino F, Baldessarini RJ, Kando J, et al. Clozapine and metabolites: serum concentrations and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994; 4: 119–25

    Google Scholar 

  24. Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with clozapine and fluoxetine or valproate. Am J Psychiatry 1994; 151: 123–5

    PubMed  CAS  Google Scholar 

  25. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serotonin reuptake inhibitors alter metabolism of clozapine. Am J Psychiatry. 1996; 153: 820–2

    PubMed  CAS  Google Scholar 

  26. Guengerich FP. Human cytochrome P-450 enzymes. Life Sci 1992; 50: 1471–8

    Article  PubMed  CAS  Google Scholar 

  27. Brøsen K, The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 1993; 71: 1002–9

    Article  PubMed  Google Scholar 

  28. Dahl-Puustinen ML, Liden A, Alm C, et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78–81

    Article  PubMed  CAS  Google Scholar 

  29. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234–40

    Article  Google Scholar 

  30. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257–68

    Article  PubMed  CAS  Google Scholar 

  31. Goff DC, Midha KK, Brotman AW, et al. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991; 148: 790–2

    PubMed  CAS  Google Scholar 

  32. Llerena A, Dahl ML, Ekqvist B, et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype. Ther Drug Monit 1992; 14: 261–4

    Article  PubMed  CAS  Google Scholar 

  33. Koreen AR, Lieberman JA, Kronig M, et al. Cross-tapering clozapine and risperidone [letter]. AmJ Psychiatry 1995; 152: 1690

    CAS  Google Scholar 

  34. McCarthy RH, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiatry 1995; 28: 61–3

    Article  PubMed  CAS  Google Scholar 

  35. Tyson SC, DeVane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995; 152: 1401–2

    PubMed  CAS  Google Scholar 

  36. Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotics. Arch Gen Psychiatry 1995; 52: 1071–2

    Article  PubMed  CAS  Google Scholar 

  37. Baldessarini RJ, Tarazi FI, Kula NS, et al. Supersensitivity of D4 receptors induced by clozapine. Arch Gen Psychiatry. In press

  38. Lake C, Casey D, McEvoy J, et al. The ‘pros and cons’ of anticholinergic prophylaxis. Psychopharmacol Bull 1986; 22: 981–4

    PubMed  CAS  Google Scholar 

  39. Arana GW, Goff DC, Baldessarini RJ, et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988; 145: 993–6

    PubMed  CAS  Google Scholar 

  40. McEvoy J. The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol 1983; 3: 288–302

    Article  PubMed  CAS  Google Scholar 

  41. Comaty J, Janicak P, Rajaratnam J, et al. Is maintenance antiparkinsonian treatment necessary? Psychopharmacol Bull 1990; 26: 267–70

    PubMed  CAS  Google Scholar 

  42. World Health Organization. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 1990; 156: 412–3

    Article  Google Scholar 

  43. Barnes T. Comment on WHO consensus statement. Br J Psychiatry 1990; 156: 413–4

    Article  PubMed  CAS  Google Scholar 

  44. Manos N, Gkiouzepas J, Logothetis J. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. Am J Psychiatry 1981; 138: 184–8

    PubMed  CAS  Google Scholar 

  45. Manos N, Gkiouzepas J, Tzotzoras T, Tzanetoglou A. Gradual withdrawal of antiparkinson medication in chronic schizophrenics. J Nerv Ment Dis 1981; 169: 659–61

    Article  PubMed  CAS  Google Scholar 

  46. Tune LE, Strauss ME, Lew MF, et al. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1460–2

    PubMed  CAS  Google Scholar 

  47. Baker LA, Cheng LY, Amara IB. Withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 1983; 143: 584–90

    Article  PubMed  CAS  Google Scholar 

  48. Hitri A, Craft RB, Fallon J, et al. Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients. Psychopharmacol Bull 1987; 23: 33–7

    PubMed  CAS  Google Scholar 

  49. McEvoy JP, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs. Compr Psychiatry 1989; 30: 135–8

    Article  PubMed  CAS  Google Scholar 

  50. Strauss ME, Reynolds KS, Jayaram G, et al. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res 1990; 3: 127–9

    Article  PubMed  CAS  Google Scholar 

  51. DiMascio A, Bernardo D, Greenblatt D, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599–602

    Article  PubMed  CAS  Google Scholar 

  52. Fann WE, Lake CR. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976; 133: 940–3

    PubMed  CAS  Google Scholar 

  53. McEvoy JP, McCue M, Spring B, et al. Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers. Am J Psychiatry 1987; 144: 573–7

    PubMed  CAS  Google Scholar 

  54. Gelenberg A, Van Putten T, Lavori P, et al. Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol 1989; 9: 180–5

    Article  PubMed  CAS  Google Scholar 

  55. Baldessarini RJ, Frankenburg R. Clozapine — a novel antipsychotic agent. N Engl J Med 1991; 324: 746–54

    Article  PubMed  CAS  Google Scholar 

  56. Granacher Jr RP, Baldessarini RJ. Physostigmine: its use in acute anticholinergic syndrome with antidepressant and anti-parkinson drugs. Arch Gen Psychiatry 1975; 32: 375–80

    Article  PubMed  CAS  Google Scholar 

  57. Schuster P, Gabriel E, Kufferle B, et al. Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 1977; 10: 437–41

    Article  PubMed  CAS  Google Scholar 

  58. Roth A, Akyol S, Nelson JC. Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry 1994; 55: 492–5

    PubMed  CAS  Google Scholar 

  59. Rivera-Calimlim L, Castaneda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther 1973; 14: 978–86

    PubMed  CAS  Google Scholar 

  60. Rivera-Calimlim L, Nasrallah H, Strauss J, et al. Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. Am J Psychiatry 1976; 133: 646–52

    PubMed  CAS  Google Scholar 

  61. Gautier J, Jus A, Villeneuve A, et al. Influence of the antiparkinsonian drugs on the plasma level of neuroleptics. Biol Psychiatry 1977; 12: 389–99

    PubMed  CAS  Google Scholar 

  62. Singh MM, Smith JM. Reversal of some therapeutic effects of an antipsychotic agent by an anti-parkinson drug. J Nerv Ment Dis 1973; 157: 50–8

    Article  PubMed  CAS  Google Scholar 

  63. Singh MM, Kay SR. Therapeutic reversal with benztropine in schizophrenics: practical and theoretical significance. J Nerv Ment Dis 1975; 160: 258–66

    Article  PubMed  CAS  Google Scholar 

  64. Johnstone EC, Crowe TJ, Ferrier IN. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychiatr Med 1983; 13: 513–27

    Article  CAS  Google Scholar 

  65. Johnstone EC, Frith CD, Crow TJ, et al. The Northwick Park ‘functional’ psychosis study: diagnosis and treatment response. Lancet 1988; II: 119–25

    Article  Google Scholar 

  66. Tandon R, Mann NA, Eisner WH, et al. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 1989; 31: 235–41

    Article  Google Scholar 

  67. Hanlon TE, Schoenrich C, Freinek W, et al. Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients. Psychopharmacologia 1966; 9: 328–39

    Article  PubMed  CAS  Google Scholar 

  68. Johnson DAW. Observations on the dose regime of fluphenazine decanoate in maintenance therapy of schizophrenia. Br J Psychiatry 1975; 126: 457–61

    Article  PubMed  CAS  Google Scholar 

  69. Gerlach J, Rasmussen PT, Hansen L, et al. Antiparkinsonian agents and long-term neuroleptic treatment. Acta Psychiatr Scand 1977; 55: 251–60

    Article  PubMed  CAS  Google Scholar 

  70. Chien CP, Castaldo V, Thornton A, et al. Prophylactic usage of antiparkinsonian drugs for akinesia. Psychopharmacol Bull 1979; 15: 75–7

    PubMed  CAS  Google Scholar 

  71. Hansen LB, Elley J, Christensen TR, et al. Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. Br J Clin Pharmacol 1979; 7: 75–80

    Article  PubMed  CAS  Google Scholar 

  72. Simpson GM, Cooper TB, Bark N, et al. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Arch Gen Psychiatry 1980; 37: 205–8

    Article  PubMed  CAS  Google Scholar 

  73. Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal. Arch Gen Psychiatry 1984; 41: 1030–5

    Article  PubMed  CAS  Google Scholar 

  74. Otani K, Hirano T, Kindo T, et al. Biperiden and piroheptine do not affect the serum level of zotepine, a new antipsychotic drug. Br J Psychiatry 1990; 157: 128–30

    Article  PubMed  CAS  Google Scholar 

  75. Rockland L, Cooper T, Schwartz F, et al. Effects of trihexyphenidyl on plasma chlorpromazine in young schizophrenics. Can J Psychiatry 1990; 35: 604–7

    PubMed  CAS  Google Scholar 

  76. Goff D, Arana G, Greenblatt D, et al. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991; 11: 106–12

    PubMed  CAS  Google Scholar 

  77. Tandon R, Greden JF, Silk KR. Treatment of negative schizophrenic symptoms with trihexyphenidyl. J Clin Psychopharmacol 1988; 8: 212–5

    Article  PubMed  CAS  Google Scholar 

  78. Tandon R, Silk KR, Greden JF, et al. Positive and negative symptoms in schizophrenia and the dexamethasone suppression test. Biol Psychiatry 1989; 25: 785–8

    Article  Google Scholar 

  79. Baldessarini RJ, Willmuth RL. Psychotic reactions during amitriptyline therapy. Can Psychiatr Assoc J 1968; 13: 571–3

    PubMed  CAS  Google Scholar 

  80. Siris SG, Morgan V, Fagerstrom R, et al. Adjunctive imipramine in the treatment of postpsychotic depression. Arch Gen Psychiatry 1987; 44: 533–9

    Article  PubMed  CAS  Google Scholar 

  81. Plasky P. Antidepressant usage in schizophrenia. Schizophrenia Bull 1991; 17: 649–57

    CAS  Google Scholar 

  82. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antimanic and antidepressant agents. In: Harden W, Rudin W, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 431–59

    Google Scholar 

  83. VanPutten T, May PRA. Akinetic depression in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101–7

    Article  CAS  Google Scholar 

  84. Spiker D. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142: 430–6

    PubMed  CAS  Google Scholar 

  85. Anton Jr RF, Burch Jr EA. Amoxapine vs. amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990; 147: 1203–8

    PubMed  Google Scholar 

  86. Kocsis JH, Croughan JL, Katz MM, et al. Response to treatment with antidepressants of patients with severe or moderate non-psychotic depression and of patients with psychotic depression. Am J Psychiatry 1990; 147: 621–4

    PubMed  CAS  Google Scholar 

  87. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992; 149: 733–45

    PubMed  CAS  Google Scholar 

  88. El-Yousef MK, Manier DH. Tricyclic antidepressants and phe nothiazines [letter]. JAMA 1974; 229: 1419

    Article  PubMed  CAS  Google Scholar 

  89. Loga S, Curry C, Lader M. Interaction of chlorpromazine and nortriptyline in patients with schizophrenia. Clin Pharmacokinetics 1981; 6: 454–62

    Article  CAS  Google Scholar 

  90. Rasheed A, Javed MA, Nazir S, et al. Interaction of chlorpromazine with tricyclic antidepressants in schizophrenic patients. J Pakistani Med Assoc 1994; 44: 233–4

    CAS  Google Scholar 

  91. Gram LF, Overo KF. Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man [letter]. BMJ 1972; 1: 463

    Article  PubMed  CAS  Google Scholar 

  92. Gram LF, Overo K, Kirk L. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. Am J Psychiatry 1974; 131: 863–6

    PubMed  CAS  Google Scholar 

  93. Nelson JC, Jatlow PI. Neuroleptic effect on desipramine steady state plasma concentrations [letter]. Am J Psychiatry 1980; 137: 1232

    PubMed  CAS  Google Scholar 

  94. Siris SG, Cooper TB, Rifkin AE, et al. Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate. Am J Psychiatry 1982; 139: 104–6

    PubMed  CAS  Google Scholar 

  95. Linnet K. Comparison of the kinetic interactions of the neuroleptics perphenazine and zuclopenthixol with tricyclic antidepressives. Ther Drug Monit 1995; 17: 308–11

    Article  PubMed  CAS  Google Scholar 

  96. Kragh-Sorensen P, Borga O, Garle M, et al. Effect of simultaneous treatment with low doses of perphenazine on plasma and urine concentrations of nortriptyline and 10-hydroxynortriptyline. Eur J Clin Pharmacol 1977; 19: 479–83

    Article  Google Scholar 

  97. Leestma JE, Koenig KL. Sudden death and phenothiazines. Arch Gen Psychiatry 1968; 18: 137–48

    Article  Google Scholar 

  98. Bigger JT, Kantor SJ, Glassman AH, et al. Cardiovascular effects of tricyclic antidepressant drugs. In: Lipton MA, DiMascio A, Killam KF, editors. Psychopharmacology: a generation of progress. New York: Raven, 1978: 1033–46

    Google Scholar 

  99. Wilens T, Stern TA. Ventricular tachycardia associated with desipramine and thioridazine. Psychosomatics 1990; 31: 100–3

    Article  PubMed  CAS  Google Scholar 

  100. Weigmann H, Muller H, Dahmen N, et al. Interactions of fluvoxamine with the metabolism of clozapine [letter]. Pharmacopsychiatry 1993; 26: 209

    Google Scholar 

  101. Szegedi A, Wiesner J, Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995; 15: 141–3

    Article  PubMed  CAS  Google Scholar 

  102. Goff D, Midha K, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995; 117: 417–23

    Article  PubMed  CAS  Google Scholar 

  103. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 1352–3

    Google Scholar 

  104. Brod TM. Fluoxetine and extrapyramidal side effects [letter]. Am J Psychiatry 1989; 146: 1353

    Google Scholar 

  105. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989; 146: 399–400

    PubMed  CAS  Google Scholar 

  106. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol 1990; 10: 48–50

    Article  PubMed  CAS  Google Scholar 

  107. Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine [letter]. Am J Psychiatry 1991; 148: 683

    PubMed  CAS  Google Scholar 

  108. Ketai R. Interaction between fluoxetine and neuroleptics. Am J Psychiatry 1993; 150: 836–7

    PubMed  CAS  Google Scholar 

  109. Lipinski JF, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42

    PubMed  Google Scholar 

  110. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152: 122–5

    PubMed  CAS  Google Scholar 

  111. Budman C, Bruun R. Persistent dyskinesia in patient receiving fluoxetine [letter]. Am J Psychiatry 1991; 148: 1403

    PubMed  CAS  Google Scholar 

  112. Fallon B, Liebowitz M. Fluoxetine and extrapyramidal symptoms in CNS lupus. J Clin Psychopharmacol 1991; 11: 147–8

    Article  PubMed  CAS  Google Scholar 

  113. Meitzer HY, Young M, Metz J, et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979; 45: 165–75

    Article  Google Scholar 

  114. Reccoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine [letter]. J Clin Psychiatry 1990; 51: 487

    PubMed  CAS  Google Scholar 

  115. Baldessarini RJ, Marsh ER, Kula NS. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res 1992; 579: 152–6

    Article  PubMed  CAS  Google Scholar 

  116. Horrigan JP, Barnhill LJ. Paroxetine-pimozide drug interaction. J Am Acad Child Adolesc Psychiatry 1994; 33: 1060–1

    Article  PubMed  CAS  Google Scholar 

  117. Arya DK, McKenzie J, Worrall N. Exacerbation of extrapyramidal symptoms with paroxetine. Austr NZ J Psychiatry 1995; 29: 521–2

    CAS  Google Scholar 

  118. Budman CL, Sherling M, Bruun RD. Combined pharmacotherapy risk. J Am Acad Child Adolesc Psychiatry 1995; 34: 263–4

    Article  PubMed  CAS  Google Scholar 

  119. Malek-Ahmadi P, Allen SA. Paroxetine-molindone interaction. J Clin Psychiatry 1995; 56: 82–3

    PubMed  CAS  Google Scholar 

  120. Wolfersdorf M, Barg T, Konig F, et al. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression. Pharmacopsychiatry 1995; 28: 56–60

    Article  PubMed  CAS  Google Scholar 

  121. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51: 302–8

    Article  PubMed  CAS  Google Scholar 

  122. Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995; 31: 347–53

    Article  PubMed  CAS  Google Scholar 

  123. Ahmed I, Dagincourt PG, Miller LG. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 1993; 38: 62–3

    PubMed  CAS  Google Scholar 

  124. Hansen-Grant S, Silk KR, Guthrie S. Fluoxetine-pimozide interaction. Am J Psychiatry 1993; 150: 1751–2

    PubMed  CAS  Google Scholar 

  125. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–13

    PubMed  CAS  Google Scholar 

  126. D’Souza DC, Bennett A, Abi-Dargham A, et al. Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperi-dol-treated schizophrenic patient. J Clin Psychopharmacol 1994; 14: 361–3

    Article  PubMed  Google Scholar 

  127. Yasui N, Otani K, Kaneko S, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995; 17: 333–5

    Article  PubMed  CAS  Google Scholar 

  128. Barbhaiya RH, Shukla UA, Greene DS, et al. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 1996; 16: 26–34

    Article  PubMed  CAS  Google Scholar 

  129. Hansen J, Siersbaek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin in warfarin metabolism in man. Clin Pharmacol Ther 1971; 12: 539–43

    PubMed  CAS  Google Scholar 

  130. Birkmayer B, editor. Epileptic seizures, behavior, and pain. Berne: Hans Huber, 1976

    Google Scholar 

  131. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. J Clin Psychopharmacol 1991; 11: 306–13

    PubMed  CAS  Google Scholar 

  132. Linnoila M, Viukari M, Vaisanen K, et al. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980; 137: 819–21

    PubMed  CAS  Google Scholar 

  133. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991; 52: 23–5

    PubMed  CAS  Google Scholar 

  134. Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985; 5: 106–9

    Article  PubMed  CAS  Google Scholar 

  135. Kidron R, Averbuch I, Klein E, et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 1985; 20: 219–22

    Article  PubMed  CAS  Google Scholar 

  136. Arana GW, Goff DC, Friedman H, et al. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 1986; 143: 650–1

    PubMed  CAS  Google Scholar 

  137. Kahn EM, Schulz C, Perel JM, et al. Change in haloperidol level due to carbamazepine. J Clin Psychopharmacol 1990; 10: 54–7

    Article  PubMed  CAS  Google Scholar 

  138. Fast DK, Jones BD, Kusalic M, et al. Effect of carbamazepine on neuroleptic plasma level and efficacy. Am J Psychiatry 1986; 143: 117–8

    PubMed  CAS  Google Scholar 

  139. Ereshefsky L, Davis CM, Harrington CA. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol 1984; 4: 138–42

    Article  PubMed  CAS  Google Scholar 

  140. Kanter GL, Yerevanian BI, Ciccone JR. Case report of a possible interaction between neuroleptics and carbamazepine. Am J Psychiatry 1984; 141: 1101–2

    PubMed  CAS  Google Scholar 

  141. Yerevanian BI, Hodgman CH. A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder. Am J Psychiatry 1985; 142: 785–6

    PubMed  CAS  Google Scholar 

  142. Centorrino F, Baldessarini RJ, Flood JG, et al. Relation of leukocyte counts during clozapine treatment to serum concentration of clozapine and metabolites. Am J Psychiatry 1995; 152: 610–2

    PubMed  CAS  Google Scholar 

  143. Tohen M, Castillo J, Baldessarini RJ, et al. Blood dyscrasias during treatment with carbamazepine and valproate vs. antidepressants. Am J Psychiatry 1995; 152: 413–8

    PubMed  CAS  Google Scholar 

  144. Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine [letter]. Pharmacopsychiatry 1993; 26: 262

    Article  PubMed  CAS  Google Scholar 

  145. Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine [letter]. Am J Psychiatry 1993; 150: 169

    PubMed  CAS  Google Scholar 

  146. Bourgeois BFD. Pharmacologic interactions between valproate and other drugs. Am J Med 1988; 84: 9–33

    Article  Google Scholar 

  147. Balfour JA, Bryson HM. Valproic acid: a review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs 1994; 2: 144–73

    Article  Google Scholar 

  148. Kando JC, Tohen M, Castillo J, et al. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994; 55: 255–7

    PubMed  CAS  Google Scholar 

  149. Baldessarini RJ, Centorrino F, Flood JG, et al. Tissue concentrations of clozapine and its metabolites in the rat. Neu-ropsychopharmacology 1993; 9: 117–24

    CAS  Google Scholar 

  150. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994; 36: 487–8

    Article  PubMed  CAS  Google Scholar 

  151. Longo LP, Salzman C. Valproic acid effects on serum concentration of clozapine and norclozapine [letter]. Am J Psychiatry 1995; 152: 650

    PubMed  CAS  Google Scholar 

  152. Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. Psychopharmacology 1994; 116: 115–6

    Article  PubMed  CAS  Google Scholar 

  153. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995; 28: 26–8

    Article  PubMed  CAS  Google Scholar 

  154. Emrich M, Okuma T, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984

    Google Scholar 

  155. Vajda FJE. New anticonvulsants. Curr Opinion Neurol Neurosurg 1992; 5: 519–25

    CAS  Google Scholar 

  156. Patsalos PN, Duncan JS. New antiepileptic drugs: a review of their current status and clinical potential. CNS drugs 1994; 2: 40–77

    Article  Google Scholar 

  157. Anderson GD, Graves NM. Drug interactions with anti-epileptic agents: prevention and management. CNS Drugs 1994; 2: 268–79

    Article  CAS  Google Scholar 

  158. Risby ED, Epstein CM, Jewart D, et al. Clozapine-induced EEG abnormalities and clinical response to clozapine. J Neuropsychiatry Clin Neurosci 1995; 7: 466–70

    PubMed  CAS  Google Scholar 

  159. Wilson WH. Do anticonvulsants hinder clozapine treatment? Biol Psychiatry 1995; 37: 132–3

    Article  PubMed  CAS  Google Scholar 

  160. Zarate Jr CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56: 411–7

    PubMed  Google Scholar 

  161. Cohen WJ, Cohen NH. Lithium carbonate, haloperidol, and irreversible brain damage. JAMA 1974; 230: 1283–7

    Article  PubMed  CAS  Google Scholar 

  162. Loudon JB, Waring H. Toxic reactions to lithium and haloperidol [letter]. Lancet 1976; II: 1088

    Article  Google Scholar 

  163. Prakash R, Kelwala S, Ban TA. Neurotoxicity with combined administration of lithium and a neuroleptic. Compr Psychiatry 1982; 23: 567–71

    Article  PubMed  CAS  Google Scholar 

  164. Sandyk R, Hurwitz MD. Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol: a report of two cases. S Afr Med J 1983; 64: 875–6

    PubMed  CAS  Google Scholar 

  165. Jeffries J, Remington G, Wilkins J. The question of lithium-neuroleptic toxicity. Can J Psychiatry 1984; 29: 601–4

    PubMed  CAS  Google Scholar 

  166. Goldney RD, Spence ND. Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry 1986; 143: 882–4

    PubMed  CAS  Google Scholar 

  167. Miller F, Menninger J. Lithium-neuroleptic neurotoxicity is dose dependent. J Clin Psychopharmacol 1987; 7: 89–91

    PubMed  CAS  Google Scholar 

  168. Baastrup C, Hollnagel P, Sorensen R, et al. Adverse reactions in treatment with lithium carbonate and haloperidol. JAMA 1976; 236: 2645–6

    Article  PubMed  CAS  Google Scholar 

  169. Kane J, Rifkin A, Quitkin F, et al. Extrapyramidal side effects with lithium treatment. Am J Psychiatry 1978; 135: 851–2

    PubMed  CAS  Google Scholar 

  170. Asnis GM, Asnis D, Dunner DL, et al. Cogwheel rigidity during chronic lithium therapy. Am J Psychiatry 1979; 136: 1225–6

    PubMed  CAS  Google Scholar 

  171. Schou M. Long-lasting neurological sequelae after lithium intoxication. Acta Psychiatr Scand 1984; 70: 594–602

    Article  PubMed  CAS  Google Scholar 

  172. Pearlman CA, Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol 1986; 6: 257–73

    Article  PubMed  CAS  Google Scholar 

  173. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987; 22: 1004–20

    Article  PubMed  CAS  Google Scholar 

  174. Rosenburg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 1989; 149: 1927–31

    Article  Google Scholar 

  175. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986; 143: 1587–90

    PubMed  CAS  Google Scholar 

  176. Pope Jr HG, Keck Jr PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986; 143: 1227–33

    PubMed  Google Scholar 

  177. Keck Jr PE, Pope Jr HG, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989; 146: 914–8

    Article  Google Scholar 

  178. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146: 717–25

    PubMed  CAS  Google Scholar 

  179. Deng MZ, Chen GQ, Phillips MR. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics. Am J Psychiatry 1990; 147: 1149–55

    PubMed  CAS  Google Scholar 

  180. Keck Jr PE, Pope Jr HG, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991; 148: 880–2

    PubMed  Google Scholar 

  181. Blake LM, Marks RC, Luchins DJ. Reversible neurologic symptoms with clozapine and lithium. J Clin Psychopharmacol 1992; 12: 97–9

    Article  Google Scholar 

  182. Baldessarini RJ, Stephens J. Lithium carbonate for affective disorder: clinical pharmacology and toxicology. Arch Gen Psychiatry 1970; 22: 72–7

    Article  PubMed  CAS  Google Scholar 

  183. Garcia G, Crismon ML, Dorson PG. Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol 1994; 14: 426–8

    PubMed  CAS  Google Scholar 

  184. Salzman C, Green AI, Rodriguez-Villa F, et al. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 1986; 27 Suppl.: 17–22

    Article  PubMed  CAS  Google Scholar 

  185. Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989; 146: 1598–601

    PubMed  CAS  Google Scholar 

  186. Barbee JG, Mancuso DM, Freed CR, et al. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 1992; 149: 506–10

    PubMed  CAS  Google Scholar 

  187. Lerner Y, Lwow E, Levitan A, et al. Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 1979; 136: 1061–4

    PubMed  CAS  Google Scholar 

  188. Modell JG, Lenox RH, Weiner S. Inpatient clinical trial of lor-azepam for the management of manic agitation. J Clin Psychopharmacol 1985; 5: 109–13

    Article  PubMed  CAS  Google Scholar 

  189. Salzman C, Solomon D, Miyawaki E, et al. Parental lorazepam versus parental haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52: 177–80

    PubMed  CAS  Google Scholar 

  190. Arana GW, Ornsteen ML, Kanter F, et al. The use of benzodiazepines for psychiatric disorders: a literature review and preliminary findings. Psychopharmacol Bull 1986; 22: 77–87

    PubMed  CAS  Google Scholar 

  191. Wolkowitz OM, Breier A, Foran AR, et al. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Arch Gen Psychiatry 1988; 143: 664–71

    Article  Google Scholar 

  192. Pato CN, Wolkowitz OM, Rapaport M, et al. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacol Bull 1989; 25: 263–6

    PubMed  CAS  Google Scholar 

  193. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148: 714–26

    PubMed  CAS  Google Scholar 

  194. Nestoros JN. Benzodiazepines in schizophrenia: a need for reassessment. Int Pharmacopsychiatry 1980; 15: 171–9

    PubMed  CAS  Google Scholar 

  195. Donaldson SR, Gelenberg AJ, Baldessarini RJ. Alternative treatments for schizophrenic psychoses. In: Berger P, Brodie HKH, editors. American handbook of psychiatry. Vol. 8. New York: Academic, 1986: 513–35

    Google Scholar 

  196. Douyon R, Angrist B, Peselow E, et al. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. Am J Psychiatry 1989; 146: 231–43

    PubMed  CAS  Google Scholar 

  197. Grohmann R, Rüther E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology 1989; 99 Suppl.: S101–4

    Article  PubMed  Google Scholar 

  198. Cobb CD, Anderson CB, Seidel DR. Possible interaction between clozapine and lorazepam. Am J Psychiatry 1991; 148: 1606–7

    PubMed  CAS  Google Scholar 

  199. Jackson CW, Mankowitz JS, Brewerton TD. Delirium associated with clozapine and benzodiazepine combinations. Ann Clin Psychiatry 1995; 7: 139–41

    Article  PubMed  CAS  Google Scholar 

  200. Frankenburg FR, Baldessarini RJ. Side effects of clozapine. N Engl J Med 1991; 325: 518–9

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, Massachusetts, USA

    Michele C. Meyer, Ross J. Baldessarini, Donald C. Goff & Franca Centorrino

  2. Department of Psychiatry, Massachusetts General Hospital, ACC-725, Boston, MA, 02114, USA

    Michele C. Meyer, Ross J. Baldessarini & Donald C. Goff

  3. Mailman Research Center, McLean Division of Massachusetts General Hospital, Belmont, Massachusetts, USA

    Ross J. Baldessarini & Franca Centorrino

  4. Lindemann Mental Health Center, Boston, Massachusetts, USA

    Donald C. Goff

Authors
  1. Michele C. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ross J. Baldessarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald C. Goff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Franca Centorrino
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Meyer, M.C., Baldessarini, R.J., Goff, D.C. et al. Clinically Significant Interactions of Psychotropic Agents with Antipsychotic Drugs. Drug-Safety 15, 333–346 (1996). https://doi.org/10.2165/00002018-199615050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199615050-00004